Vascular Response to Everolimus and Biolimus-Eluting Coronary Stents Versus Everolimus-Eluting Bioresorbable Scaffolds: An Optical Coherence Tomography Substudy of the Everbio Ii Trial

Kallinikou, Zacharenia; Puricel, Serban; Lehmann, Sonja; Arroyo, Diego; Togni, Mario; Cook, Malica; Baeriswyl, Gérard; Stauffer, Jean Christophe; Goy, Jean‐Jácques; Cook, Stéphane

doi:10.1016/s0735-1097(15)61763-6

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a post hoc analysis of 44 unmatched patients, comparable rates of uncovered struts at 12 months were found for BVS and second-generation DES 10 . In the EVERBIO II trial, BVS showed a lower uncoverage rate at nine months compared with BP biolimus-eluting stents 11 . In the recently published TROFI II trial 12 , a better healing score was observed with BVS at six months compared with a durable polymer everolimus-eluting stent, implanted in primary angioplasty.…”

Section: Vascular Healing After Implantation Of Bvs and Metallic Desmentioning

confidence: 94%

Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: the ESTROFA OCT BVS vs. BP-DES study

Gonzalo¹,

Otaegui²,

Rumoroso³

et al. 2018

EuroIntervention

View full text Add to dashboard Cite

Aims:We sought to compare vascular healing with bioresorbable everolimus-eluting vascular scaffolds (BVS) and drug-eluting stents with bioabsorbable polymers (BP-DES) at six and 12 months both implanted in the same patients.Methods and results: This was a multicentre and prospective study including patients with at least two comparable lesions to treat. In every patient both BVS and BP-DES (SYNERGY, Orsiro or BioMatrix Flex) were implanted by lesion randomisation. Patients included were evaluated with optical coherence tomography at six or 12 months (2:1). Finally, 68 patients had an examination at six months and 27 patients at 12 months. The rates of uncovered struts at six months were 1.7±3.2% for BVS and 5.3±5.6% for BP-DES (p=0.0001), and at 12 months 0.48±0.72% and 4.8±5%, respectively (p=0.001). Rates of strut malapposition were significantly lower with BVS. There was no significant intra-patient correlation with BP-DES/ BVS for endpoints. Evaginations were more frequent and larger with BVS. Discontinuities in BVS were observed in 19.4% at six months and 14.3% at 12 months.Conclusions: Vascular healing with BVS and BP-DES could be more device-specific than patient-specific.At follow-up, BVS presented fewer uncovered or non-apposed struts than BP-DES but more frequent and larger evaginations. Discontinuities in BVS were relatively frequent at both time points.

show abstract

Section: Vascular Healing After Implantation Of Bvs and Metallic Desmentioning

confidence: 94%

Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: the ESTROFA OCT BVS vs. BP-DES study

Gonzalo¹,

Otaegui²,

Rumoroso³

et al. 2018

EuroIntervention

View full text Add to dashboard Cite

show abstract

“…Representative images of OCT analyses for both BVS and DES are provided in one of our previous publications. 9 Neointima area was defined as stent area minus lumen area. Struts were classified into either apposed, protruding or malapposed.…”

Section: Methodsmentioning

confidence: 99%

Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial

et al. 2018

Self Cite

View full text Add to dashboard Cite

AimsTo compare endothelium-dependent vasomotor function and vascular healing 15 months after implantation of two new-generation drug-eluting stents and biovascular scaffolds (BVS).Methods and resultsA total of 28 patients previously treated with a SYNERGY stent (bioabsorbable polymer everolimus-eluting stents (BP-EES)), a PROMUS stent (persistent polymer everolimus-eluting stents (PP-EES)) or an ABSORB (BVS) underwent control coronary angiography, 15 months after implantation, coupled with optical coherence tomography imaging and supine bicycle exercise. Intracoronary nitroglycerin was administered after exercise testing. Coronary vasomotor response was assessed using quantitative coronary angiography at rest, during supine bicycle exercise and after nitroglycerin. The primary end point was the percent change in mean lumen diameter compared with baseline. Secondary end points were strut coverage and apposition.There were no significant differences in vasomotor response between the three treatment groups. Patients with PP-EES showed significant vasoconstriction of the proximal peristent segment at maximum exercise (P=0.02). BP-EES (2.7%, 95% CI 0 to 5.5) and BVS (3.2%, 95% CI 0 to 6.7) showed less uncovered struts than PP-EES (12.1%, 95% CI 2.9 to 21.3, P=0.02 and 0.09, respectively). Complete strut apposition was more frequently seen with BP-EES (99.6%, 95% CI 99.2 to 100) than with BVS (98.9%, 95% CI 98.2 to 99.6, P=0.04) or PP-EES (95.0%, 95% CI 91.6 to 98.5, P=0.001).ConclusionBVS and thin strut BP-EES have a reassuring vasomotion profile, suggesting minimal endothelial dysfunction 15 months after implantation.

show abstract

Vascular Response to Everolimus and Biolimus-Eluting Coronary Stents Versus Everolimus-Eluting Bioresorbable Scaffolds: An Optical Coherence Tomography Substudy of the Everbio Ii Trial

Cited by 2 publications

References 0 publications

Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: the ESTROFA OCT BVS vs. BP-DES study

Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: the ESTROFA OCT BVS vs. BP-DES study

Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial

Contact Info

Product

Resources

About